S&P 500 7,353.73 −4.36%
Nasdaq 24,315.00 −5.52%
S&P/TSX 35,605.27 −2.03%
Apple 344.17 −1.53%
Nvidia 181.60 −9.26%
Microsoft 535.93 −3.58%
Shopify 201.23 −5.40%
Royal Bank 285.86 −2.29%
CAD/USD 0.7120 −0.52%
CLOSED · 00:50 ET
Market ClerkRecap
Fri Nov 6 · markets closed2 signals on Nov 5249 insider buys this week · $450MCIRO short report next: Nov 14The week ahead
DC
INSIDER · VNDA · Vanda Pharmaceuticals Inc. · DIRECTOR

Duncan Charles Cliff

Every open-market transaction filed under this name, Nov 3 to Nov 5.

Filings
3
3 buys · 0 sells
Bought
$38K
open market, at cost
Sold
—
includes scheduled sales
Buys since
—
no current price on file

Filings

SEC FORM 4 · OPEN MARKET
TradedTickerCompanyRoleTypeSharesPriceValueSince
Nov 5VNDAVanda Pharmaceuticals Inc.DirectorBuy5,803$3.80$22K—
Nov 4VNDAVanda Pharmaceuticals Inc.DirectorBuy3,447$3.82$13K—
Nov 3VNDAVanda Pharmaceuticals Inc.DirectorBuy750$3.80$3K—

"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.